OPIOID RECEPTOR BLOCKADE IN TREATING ALCOHOL USE DISORDERS

    公开(公告)号:US20180371542A1

    公开(公告)日:2018-12-27

    申请号:US16019091

    申请日:2018-06-26

    Inventor: Raymond F. Anton

    Abstract: Provided are methods for treating alcohol use disorders using opioid receptor antagonists. In some embodiments, the presently disclosed methods include assaying nucleic acid from a subject regarding the subject's genotype with respect to the COMT and OPRM1 genes and administering or not administering an opioid receptor antagonist to the subject on the basis therefore. Also provided are methods for detecting susceptibility to an opioid receptor antagonist therapy for disorders associated with opioid receptor activity and methods for identifying and treating human subjects having susceptibility to opioid receptor antagonist therapies for disorders associated with opioid receptor activity.

    Antifibrotic effects of oxetanyl sulfoxides

    公开(公告)号:US09676738B2

    公开(公告)日:2017-06-13

    申请号:US15293107

    申请日:2016-10-13

    CPC classification number: C07D305/08 C07D305/06

    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of wherein Z is aryl or substituted aryl, heteroaryl, or substituted heteroaryl; X is —S—, —S(O)—, or S(O)2—; R20 and R21 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, or halogenated alkyl; one of R22, R23, and R24 is —O— and the others of R22, R23 and R24 are independently —CH2—, or —C(R13)— wherein R13 is alkyl, alkenyl, alkynyl, trialkylsilyl group, or —(CH2)mOR15, wherein R15 is alkyl or an aryl and m is an integer in the range of 1 to 10; and R25 is H, alkyl, substituted alkyl, halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C3 alkoxy, aryloxy, or —(CH2)qOR17, wherein R17 is alkyl an aryl and q is an integer in the range of 1 to 10.

    Systems and methods for determining white matter fiber tractography
    36.
    发明授权
    Systems and methods for determining white matter fiber tractography 有权
    用于确定白质纤维束图的系统和方法

    公开(公告)号:US09478026B2

    公开(公告)日:2016-10-25

    申请号:US14673991

    申请日:2015-03-31

    Abstract: One aspect of the present disclosure relates to a system that can determine a kurtosis diffusion orientation distribution function (dODF) that can, for example, be used with diffusional kurtosis imaging fiber tractography (DKI-FT). The system can include a non-transitory memory storing computer-executable instructions and a processor that executes the computer-executable instructions to perform the following operations. Diffusion magnetic resonance imaging (dMRI) data can be received. Based on the dMRI data, a diffusion tensor (DT) and a diffusional kurtosis tensor (DKT) can be determined. A kurtosis dODF can be determined for the dMRI data based on the DT and the DKT. The kurtosis dODF extends a Gaussian approximation of the DT to include non-Gaussian corrections of the DKT.

    Abstract translation: 本公开的一个方面涉及一种可以确定峰值扩散取向分布函数(dODF)的系统,其可以例如与扩散峭度成像纤维束图(DKI-FT)一起使用。 该系统可以包括存储计算机可执行指令的非暂存存储器和执行计算机可执行指令以执行以下操作的处理器。 可以接收扩散磁共振成像(dMRI)数据。 基于dMRI数据,可以确定扩散张量(DT)和弥散张度张量(DKT)。 可以基于DT和DKT来确定dMRI数据的峰度dODF。 峰度dODF扩展了DT的高斯近似,以包括DKT的非高斯校正。

Patent Agency Ranking